Apothecary Pharma recalls 22 lots of compounded tirzepatide over sterility concerns

Apothecary Pharma is voluntarily recalling 22 lots of compounded tirzepatide, the active ingredient in Mounjaro and Zepbound, according to an FDA notice dated October 20, 2026 ^[1]. The recall covers 18 mg/mL, 4 mL sterile multi-dose vials of the injectable drug made by the Cary, North Carolina compounding pharmacy ^[1].

The action follows an FDA warning letter issued in December 2025, after inspectors visited Apothecary's facility at 1913 Evans Road in Cary. The letter cited "serious deficiencies in … practices for producing drug products intended or expected to be sterile, which put patients at risk" ^[1]. In September, Apothecary said it was launching a voluntary recall of its compounded tirzepatide injection and notified customers by letter ^[1]. The FDA has since classified the recall as Class II, which the agency uses for products that carry a moderate risk of temporary or medically reversible health consequences; the risk of serious harm is described as low ^[1].

Tirzepatide is the molecule Eli Lilly sells as Mounjaro for type 2 diabetes and Zepbound for obesity. Lilly has said it does not sell or distribute tirzepatide to compounding pharmacies or to other sources such as medical spas and online retailers, and it has warned the public against using compounded versions ^[1]. The company said testing of compounded and counterfeit versions of the drug found bacterial contamination, altered chemical structures, high impurity levels and, in some cases, products with no active ingredient at all ^[1]. The two tirzepatide brands accounted for two-thirds of Lilly's total revenue in the second quarter of this year ^[1].

Compounded tirzepatide has been a contested category. Under U.S. law, compounding pharmacies should not be able to sell copycat versions of the drug since it was removed from the shortage list in late 2024 or early 2025 ^[1]. Some companies have continued to supply it under Section 503A, a framework that lets pharmacies make small quantities of a drug for individual patients whose needs, they say, are not met by a standard formulation ^[1]. Tactics used to keep selling include changing the dosage strength, removing an allergen or preservative, or combining the active ingredient with another component such as vitamin B12 ^[1]. Lawsuits between drugmakers and compounding companies over these products are ongoing ^[1].

This is not the first sterility-related recall in the GLP-1 market. Compounded semaglutide — the molecule in Ozempic, Wegovy and Rybelsus — has been recalled by Apollo Care, Idexis, ProRx and Aequita Pharmacy, among others ^[1]. The FDA has also sent warning letters to companies accused of selling unapproved versions of tirzepatide, semaglutide and Lilly's still-experimental retatrutide ^[1]. The agency has heightened its scrutiny of compounded incretin therapies for weight loss and type 2 diabetes after a surge in manufacturing and sterility concerns ^[1].

Why it matters for patients

A sterile injectable that is not actually sterile can introduce bacteria into the body, and the FDA's warning letter tied the manufacturing problems directly to patient risk ^[1]. The Class II label means the agency expects most harm, if any, to be temporary or reversible, but it still treats the recall as a meaningful safety event ^[1].

People who get tirzepatide through a compounding pharmacy rather than a standard prescription have no way to verify sterility from the outside of a vial, and the FDA's findings concern how the product was made, not how it looks. The recall is specific to Apothecary Pharma's 18 mg/mL, 4 mL multi-dose vials, so it does not by itself describe other compounding pharmacies' products ^[1]. The notice does not say how many vials or patients are affected, and it does not describe any reported injuries.

What happens next

Apothecary notified customers by letter in September, and the FDA posted the notice and assigned the Class II classification on October 20, 2026 ^[1]. The recall notice does not state how many vials have been returned, whether any remain in patients' hands, or when the recall is expected to close; those details have not been disclosed ^[1]. The FDA's broader review of compounded incretin products, and the lawsuits between Lilly and compounding companies, are continuing ^[1].